SCHEMBL6350264

SCHEMBL6350264

CC(O)CCCCn1c(=O)c2[nH]c(CNC(=O)OC(C)(C)C)nc2n(C)c1=O

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 7/20 0.42
KDM4E B2RXH2 2/20 0.39
LMNA P02545 1/20 0.39
POLB P06746 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MEN1 O00255 1/20 0.37
PDE5A O76074 1/20 0.37
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37
BLM P54132 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
KMT2A Q03164 1/20 0.37
PDE1C Q14123 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6350262 1.00 ADORA1 (0.42) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL6348600 0.92 ADORA1 (0.42) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL6348599 0.92 ADORA1 (0.42) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL6350285 0.90 ADORA1 (0.41) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL6350287 0.90 ADORA1 (0.41) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL6347238 0.89 ADORA1 (0.40) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL6347237 0.89 ADORA1 (0.40) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL6346992 0.88 ADORA1 (0.39) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL6346988 0.88 ADORA1 (0.39) ADORA1KDM4ELMNAPOLBCYP1A2
SCHEMBL4727164 0.84 ADORA1 (0.43) ADORA1KDM4ELMNAPOLBCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1171442-B1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS CELL THERAPEUTICS INC (US) 2005-12-07 EP disclosed
US-6878715-B1 Therapeutic compounds for inhibiting interleukin-12 signals and method for using same CELL THERAPEUTICS, INC. (US) 2005-04-12 US disclosed
US-20050049262-A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same CELL THERAPEUTICS, INC. (US) 2005-03-03 US disclosed
EP-1171442-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALLING INHIBITORS CELL THERAPEUTICS, INC. (US) 2002-01-16 EP disclosed
WO-2000061583-A1 XANTHINE DERIVATIVES AND ANALOGS AS CELL SIGNALING INHIBITORS CELL THERAPEUTICS, INC. (US) 2000-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049262-A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same IL2, CCR10, CCR1 ADORA1 1499/4885KDM4E 4301/4885LMNA 767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.